Weight loss jabs such as Wegovy and Mounjaro face stricter rules set by the General Pharmaceutical Council (GPhC) following concerns over their misuse. The GPhC has implemented new prescription guidelines to prevent the inappropriate supply of these medications. Under the updated rules, individuals will no longer be able to access the drugs through online questionnaires alone. Instead, in-person or video consultations will now be mandatory to verify a patient’s BMI. Additionally, medical records or information from a GP will be required to ensure accurate prescriptions.
Pharmacists failing to adhere to these new guidelines may face enforcement actions, including fitness-to-practice investigations and the imposition of conditions like improvement plans, warns the GPhC. This move comes in response to reports from groups like the National Pharmacy Association (NPA), who raised concerns about individuals with eating disorders or low body weight receiving prescriptions for these drugs. The GPhC aims to address these issues after discovering that some online pharmacies were sidestepping necessary checks and prioritising prescription quotas over patient safety.
Popular weight-loss injections like Wegovy and Mounjaro contain semaglutide and tirzepatide, respectively, and have gained traction for their efficacy in aiding weight loss. These drugs function as appetite suppressants, with semaglutide also utilized in the treatment of type 2 diabetes under the name Ozempic. Administered as weekly injections, these drugs mimic the hormone glucagon-like peptide-1 (GLP-1) to induce feelings of fullness and regulate metabolism.
Despite their proven benefits, the concern is escalating over the inappropriate prescribing of these medications, especially through online pharmacies. The GPhC has highlighted unsafe prescribing practices and the possibility of supply issues, with some online pharmacies setting prescription quotas without due diligence. To address these issues, prescribers are now required to actively share prescription details with a patient’s GP for additional monitoring.
Weight-loss drugs are now categorised as “high risk” medicines, necessitating increased safeguards and adherence to strict NHS criteria. The National Pharmacy Association has expressed optimism that the updated guidelines will enhance patient safety, noting that the majority of pharmacies, including online sellers, already maintain good practice in this area.
In conclusion, the GPhC’s implementation of stricter rules for weight-loss jabs reflects a necessary step towards ensuring the safe and appropriate dispensing of these medications. By tightening prescription guidelines and enforcing compliance, regulators aim to safeguard individuals’ health and well-being amidst the rising popularity of weight-loss injections.